Indications and results of radioiodine treatment of differentiated thyroid cancer

被引：0
|
作者：
Riemann, B. [1 ]
机构：
[1] Univ Klinikum Munster, Klin Nukl Med, Albert Schweitzer Campus 1, Munster, Germany
来源：
CHIRURG | 2020年 / 91卷 / 12期
关键词：
Risk profile; Prognosis; Side effects; Adjuvant treatment options; Interdisciplinary treatment concept; GUIDELINES;
D O I：
10.1007/s00104-020-01248-x
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Background Malignant tumors of the thyroid gland are the most frequent malignant endocrine neoplasms, comprising approximately 1% of all malignant tumors. In recent years there has been a clear rise in the incidence of differentiated thyroid carcinomas (DTC), especially small papillary carcinomas. Objective Indications for and results of radioiodine treatment (RAI) of DTC. Material and methods A review of the current literature and guidelines of RAI in DTC was carried out. Results The use of RAI is the most important adjuvant treatment option for DTC and is generally well-tolerated. Conclusion Due to the combination of surgery and RAI the DTC has a very good prognosis compared with other cancers, with an average survival rate of more than 90%.
引用
收藏
页码：1013 / 1016
页数：4
相关论文
共 50 条
  • [31] Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
    Herranz, Urbano Anido
    [J]. CANCER MEDICINE, 2022, 11 : 47 - 53
  • [32] Results of multidisciplinary treatment, including radioiodine, in pediatric patients with differentiated thyroid carcinoma
    Stefanovic, L.
    Mihailovic, J.
    Matovina, E.
    Malesevic, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S320 - S321
  • [33] Evolution of radioiodine treatment in differentiated thyroid carcinoma
    Tamayo-Alonso, Pilar
    Garcia-Talavera, Paloma
    Montes-Fuentes, Carlos
    Martin-Gomez, Esther
    Martin-Gomez, Enrique
    Diaz-Gonzalez, Luis
    [J]. REVISTA ORL, 2022, 13 (02) : 97 - 109
  • [34] Guidelines for radioiodine therapy of differentiated thyroid cancer
    M. Luster
    S. E. Clarke
    M. Dietlein
    M. Lassmann
    P. Lind
    W. J. G. Oyen
    J. Tennvall
    E. Bombardieri
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35
  • [35] Prediction of Radioiodine Treatment Results in Patients with Well-Differentiated Thyroid Carcinoma
    Kowalczyk, A.
    Kaminski, G.
    Jurczyk, M.
    Szalus, N.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S196 - S196
  • [36] Guidelines for radioiodine therapy of differentiated thyroid cancer
    Luster, M.
    Clarke, S. E.
    Dietlein, M.
    Lassmann, M.
    Lind, P.
    Oyen, W. J. G.
    Tennvall, J.
    Bombardieri, E.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (10) : 1941 - 1959
  • [37] Differentiated thyroid cancer theranostics: radioiodine and beyond
    Choudhury, Partha S.
    Gupta, Manoj
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2018, 91 (1091):
  • [38] Guidelines for radioiodine therapy in differentiated thyroid cancer
    Dietlein, M
    Dressler, J
    Farahati, J
    Leisner, B
    Moser, E
    Reiners, C
    Schicha, H
    Schober, O
    [J]. NUKLEARMEDIZIN, 1999, 38 (6A) : 221 - 222
  • [39] Conventional Radioiodine Therapy for Differentiated Thyroid Cancer
    Ylli, Donna
    Van Nostrand, Douglas
    Wartofsky, Leonard
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2019, 48 (01) : 181 - +
  • [40] Treatment of Patients with Radioiodine-Refractory, differentiated Thyroid Cancer A Consensus Statement
    Lindner, C.
    Dierneder, J.
    Pall, G.
    Pirich, C.
    Hoffmann, M.
    Raderer, M.
    Becherer, A.
    Niederle, B.
    Lipp, R.
    Lind, P.
    Gallowitsch, H.
    Romeder, F.
    Virgolini, I.
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2015, 54 (03): : 125 - 130
12345